drugset
Drugs / Azacytidine
last change Sep 2026 re-read 3 minutes ago

Azacytidine

also known as AZA · 5' Azacytidine (AZA) · 5-Azacytidine

Other / unclassified targets DNMT1

Developed for
acute myeloid leukemia · myelodysplastic syndrome · leukemia · diffuse large B-cell lymphoma · Hodgkins lymphoma · peripheral T-cell lymphoma, not otherwise specified · acute lymphoblastic leukemia · acute monocytic leukemia
+13 more · B-cell non-Hodgkin lymphoma · carcinoma · childhood acute lymphoblastic leukemia · childhood acute myeloid leukemia · extranodal nasal NK/T cell lymphoma · germ cell tumor · lymphoma · mature T-cell and NK-cell non-Hodgkin lymphoma · melanoma · myeloid leukemia · non-Hodgkin lymphoma · non-small cell lung carcinoma · sarcoma
Investigated by
Chinese PLA General Hospital · 940 Hospital of the People's Liberation Army Joint Logistic Support Force · 960th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Celgene Corporation · Navy General Hospital, Beijing · The General Hospital of Western Theater Command
+33 more · M.D. Anderson Cancer Center · National Cancer Institute (NCI) · The First Affiliated Hospital of Soochow University · Yantai Yuhuangding Hospital · Air Force Military Medical University, China · First Affiliated Hospital of Harbin Medical University · First Hospital of China Medical University · People's Liberation Army (PLA) Strategic Support Force Characteristic Medical Center · The General Hospital of Northern Theater Command · Weill Medical College of Cornell University · Air Force Medical Center of PLA · Assistance Publique Hopitaux De Marseille · Bayer · Baylor College of Medicine · Belgian Hematological Society · Carlos Graux, MD, PhD · Center for Cell and Gene Therapy, Baylor College of Medicine · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Gateway for Cancer Research · Jining First People's Hospital · King Fahad Medical City · King's College London · Merck Sharp & Dohme LLC · PLA Strategic Support Force's Characteristic Medical Center · Peking University · Peking University Cancer Hospital & Institute · Ruijin Hospital · Shanghai Jiao Tong University School of Medicine · Swiss Cancer Institute · The Methodist Hospital Research Institute · Therapeutic Advances in Childhood Leukemia Consortium · University of Virginia · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Trials 34

today NCT06694454 · Ph 1/2 NCT07512700 · Ph 2 NCT07081607 · Ph 2 NCT06778902 · Ph 2 NCT07514936 · Ph 2 NCT06471946 · Ph 1/2 NCT06176027 · Ph 1/2 NCT06470841 · Ph 2 NCT06598384 · Ph 2 NCT06928376 · Ph 2 NCT05939180 · Ph 2/3 NCT06084819 · Ph 2 NCT06068621 · Ph 2 NCT05659992 · Ph 2 NCT05355051 · Ph 2 NCT05809167 · Ph 2 NCT05823714 · Ph 2 NCT04648826 · Ph 1/2 NCT05058755 · not/applicable NCT04899414 · Ph 2 NCT04897477 · Ph 1/2 NCT04747236 · Ph 2 NCT04904237 · Ph 2 NCT02489929 · not/applicable NCT02196857 · Ph 2 NCT02275663 · Ph 2 NCT02017457 · Ph 2 NCT01861002 · Ph 1 NCT01542684 · Ph 2 NCT01333046 · Ph 1 NCT01120834 · Ph 1/2 NCT01004991 · Ph 1/2 NCT00739388 · Ph 2 NCT00915785 · Ph 2
200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01861002 May 2013 → Jul 2014 childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia Therapeutic Advances in Childhood Leukemia Consortium Completed No outcome recorded
Phase 1 NCT01333046 Jan 2012 → Sep 2021 overdue Hodgkins lymphoma, non-Hodgkin lymphoma Baylor College of Medicine Active not recruiting No outcome recorded
Phase 1/27 trials
Phase 1/2 NCT06694454 Jul 2026 → Dec 2031 expected non-small cell lung carcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 1/2 NCT06471946 Oct 2024 → Sep 2029 expected myelodysplastic syndrome Navy General Hospital, Beijing Recruiting No outcome recorded
Phase 1/2 NCT06176027 Oct 2024 → Sep 2028 expected peripheral T-cell lymphoma, not otherwise specified Navy General Hospital, Beijing Recruiting No outcome recorded
Phase 1/2 NCT04648826 Dec 2021 carcinoma, germ cell tumor, melanoma, sarcoma National Cancer Institute (NCI) Withdrawn No outcome recorded
Phase 1/2 NCT04897477 Apr 2021 → Apr 2022 B-cell non-Hodgkin lymphoma Chinese PLA General Hospital Unknown No outcome recorded
Phase 1/2 NCT01120834 Sep 2010 → Apr 2013 lymphoma Weill Medical College of Cornell University Completed No outcome recorded
Phase 1/2 NCT01004991 Jan 2010 → Sep 2013 diffuse large B-cell lymphoma Weill Medical College of Cornell University Completed No outcome recorded
Phase 222 trials · 1 missed
Phase 2 NCT07512700 Sep 2025 → Sep 2028 expected acute monocytic leukemia Chinese PLA General Hospital Recruiting No outcome recorded
Phase 2 NCT07081607 Jul 2025 → Jul 2026 overdue peripheral T-cell lymphoma, not otherwise specified Ruijin Hospital Not yet recruiting No outcome recorded
Phase 2 NCT06778902 Feb 2025 → Jan 2028 expected diffuse large B-cell lymphoma Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Not yet recruiting No outcome recorded
Phase 2 NCT07514936 Nov 2024 → Sep 2027 expected acute myeloid leukemia Chinese PLA General Hospital Recruiting No outcome recorded
Phase 2 NCT06470841 Sep 2024 → Dec 2027 expected acute myeloid leukemia Navy General Hospital, Beijing Not yet recruiting No outcome recorded
Phase 2 NCT06598384 Sep 2024 → Sep 2030 expected acute myeloid leukemia Navy General Hospital, Beijing Not yet recruiting No outcome recorded
Phase 2 NCT06928376 Apr 2024 → Sep 2025 overdue acute myeloid leukemia Chinese PLA General Hospital Recruiting No outcome recorded
Phase 2 NCT06084819 Aug 2023 → Jan 2029 expected acute myeloid leukemia Chinese PLA General Hospital Recruiting No outcome recorded
Phase 2 NCT06068621 Mar 2023 → May 2024 acute myeloid leukemia Chinese PLA General Hospital Completed No outcome recorded
Phase 2 NCT05659992 Dec 2022 → Aug 2023 acute myeloid leukemia Chinese PLA General Hospital Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT05939180 Apr 2024 → Oct 2025 overdue acute myeloid leukemia The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase not applicable2 trials
— NCT05058755 Sep 2021 → Dec 2022 extranodal nasal NK/T cell lymphoma Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Completed No outcome recorded
— NCT02489929 Aug 2015 → Aug 2018 myelodysplastic syndrome, myeloid leukemia Assistance Publique Hopitaux De Marseille Unknown No outcome recorded
Comparator or background therapy8 trials
Phase 1 NCT02783547 Background Dec 2015 → Jun 2017 myelodysplastic syndrome SymBio Pharmaceuticals Withdrawn No outcome recorded
Phase 1/2 NCT04729543 Background Oct 2020 → Dec 2024 overdue uveal melanoma Erasmus Medical Center Recruiting No outcome recorded
Phase 1/2 NCT03030612 Background Dec 2016 → Aug 2022 acute myeloid leukemia, myelodysplastic syndrome OncoVerity, Inc. Completed No outcome recorded
Phase 1/2 NCT02400281 Background Sep 2015 → Jul 2020 acute myeloid leukemia Arog Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2 NCT05029141 Background Sep 2021 → Dec 2026 expected acute myeloid leukemia The First Affiliated Hospital of Soochow University Active not recruiting No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 42 sources stand behind the page.

FieldValueCited text
Known as Azacytidine “Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG)” NCT04716114 ↗
41

“A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)” NCT03030612 ↗

“VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.” NCT05939180 ↗

“Azacytidine is a DNA methylation transferase inhibitor that can re-express tumor suppressor genes in leukemia cells.” NCT05823714 ↗

“Azacytidine is a DNA methylation transferase inhibitor that can re-express tumor suppressor genes in leukemia cells.” NCT05809167 ↗

“All patients receive azacytidine and venetoclax as leukemia debulking treatment” NCT04904237 ↗

“azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9)” NCT05029141 ↗

“Azacytidine 75mg/(m2.d) by IV on days 1-7 of every cycle.” NCT04722952 ↗

“1. Azacytidine (75 mg/m2/day, days 1 to 7).” NCT07512700 ↗

“5' Azacytidine (AZA)” NCT04729543 ↗

NCT02400281 ↗

Show 31 more sources
Known as 5' Azacytidine (AZA) “5' Azacytidine (AZA)” NCT04729543 ↗
Known as 5-Azacytidine “A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML” NCT01861002 ↗
Known as AZA “This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of AZA（azacytidine）combined with the R-GemOx (rituximab, gemcitabine...” NCT06778902 ↗
4

“A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML” NCT01861002 ↗

“Venetoclax (VEN)+Azacytidine (AZA) Followed by Modified BUCY Conditioning Regimen” NCT05809167 ↗

“DNA demethylating agents such as decitabine (DAC) and azacytidine (AZA).” NCT04648826 ↗

“standard dose of azacytidine (AZA) in Phase 1” NCT03030612 ↗
Action Inhibit “Azacitidine is designed to block certain proteins that stop the function of tumor-fighting genes.” NCT01542684 ↗
Modality Other / unclassified “using hypomethylating agent, 5-azacytidine (AZA)” NCT01861002 ↗
Route Subcutaneous “Patients receive azacitidine subcutaneously” NCT00739388 ↗
Target DNMT1 “The dose of AZA will be sequentially increased to maximize intra-tumoral DNMT1 depletion” NCT04648826 ↗